Results from the Phase III WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps showed that AstraZeneca (AZN) and Amgen’s Tezspire demonstrated a statistically significant and clinically meaningful reduction in the size of nasal polyps and reduced nasal congestion compared to placebo. WAYPOINT is a randomized, double-blind trial that evaluated the efficacy and safety of Tezspire administered subcutaneously compared to placebo in adults with severe CRSwNP. Participants in the trial were symptomatic despite treatment with standard of care. The safety profile and tolerability of Tezspire in this trial were consistent with the known profile of the medicine. Full results will be shared with regulatory authorities and the scientific community at an upcoming medical meeting.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on AZN:
- Amgen, AstraZeneca announce top-line results from WAYPOINT trial
- QQQ ETF Update, 11/6/2024
- AstraZeneca selloff on China news ‘feels far overdone,’ says Barclays
- AstraZeneca upgraded to Hold from Sell at Deutsche Bank
- AstraZeneca (AZN) Shares Drop as China Probe Risks Loom
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
